Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 4, 2002, Pages 980-986

  Fisher, Barbara ^a   Won, M ^b,c   Macdonald, David ^a,b   Johnson, Douglas W ^d   Roa, Wilson ^e  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c RTOG Statistical Unit   (United States)

^d Baptist Regional Cancer Institute   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Camptothecin; Glioblastoma multiforme; Radiosensitizers; Radiotherapy; Topotecan

Indexed keywords

CHEMOTHERAPY; PATIENT TREATMENT; RADIOTHERAPY; SURGERY; TUMORS;

RADIOSENSITIZATION;

ONCOLOGY;

ANTINEOPLASTIC AGENT; TOPOTECAN;

ADULT; ARTICLE; BLOOD TOXICITY; BRAIN BIOPSY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOSENSITIZATION; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0037100154     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02817-1     Document Type: Article

References (27)

1. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
2. DNA topoisomerases in cancer therapy
3. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin
4. Topotecan: An oncologist's view
5. Clinical studies with topotecan: The EORTC experience. Proceedings of the 7th NCI-EORTC symposium on new drugs in cancer therapy
6. Plasma and cerebrospinal fluid pharmokinetic study of topotecan I nonhuman primates
7. Activity of 9-dimethylaminoethyl-10-hydroxicamptothecin against pediatric and adult central nervous system tumor xenografts
8. Topotecan treatment of adults with primary malignant glioma
9. Post-treatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells
10. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864)
11. Interaction of topoisomerase I inhibitors with radiation in cisdiamminedichlorplatinum (II)-sensitive and resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo
12. DNA topoisomerase I-targeting drugs as radiation sensitizers
13. Potentiation of radiation response in human carcinoma cells in vitro by topotecan, an inhibitor of DNA topoisomerase I
14. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation
15. Phase I and clinical pharmacologic study of intravenous topotecan
16. Phase I and pharmacologic study of topotecan (SK&F 104864): A novel topoisomerase I inhibitor
17. Phase II trials of topotecan in patients with recurrent malignant gliomas
18. Topotecan for the treatment of recurrent or progressive central nervous system tumors - A Pediatric Oncology Group phase II study
19. Phase I study of topotecan and cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group trial 9507
20. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials
21. Topotecan, as a radiosensitizer, for brainstem glioma (BSG) of childhood: First report of CCG 0952, a phase I study
22. Phase I study oftopotecan as a radiosensitizer prior to daily involved field irradiation in children with intrinsic pontine glioma: A Children's Cancer Group study
23. Schedule-dependent activity of irinotecan LUS BCNU against malignant glioma xenografts
24. Enhancement of irinotecan (CPT-11) activity again central nervous system tumor xenografts by alkylating agents
25. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethly-10-4-[1-piperidino])-carbonyloxy-camptoth against pediatric and adult central nervous system tumor xenografts